BioSyent logo.png
BioSyent Schedules Q3 and YTD 2022 Earnings Release for November 16, 2022
November 10, 2022 09:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended...
BioSyent logo.png
BioSyent Initiates First Dividend
October 12, 2022 17:45 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent logo.png
BioSyent to Present at the Virtual MicroCap Leadership Summit
September 14, 2022 16:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been selected to present at the 7th annual...
BioSyent logo.png
BioSyent Announces Adoption of Dividend Policy
August 23, 2022 16:55 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 23, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors (the “Board”) today adopted a...
BioSyent logo.png
BioSyent Releases Q2 and H1 2022 Financial Results
August 23, 2022 16:45 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 23, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2022. Key...
BioSyent logo.png
BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022
August 16, 2022 19:14 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 16, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30,...
BioSyent logo.png
BioSyent Releases Financial Results for Q1 2022
May 18, 2022 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 18, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2022. Key highlights...
BioSyent logo.png
BioSyent Schedules Q1 2022 Earnings Release for May 18, 2022
May 10, 2022 16:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 10, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2022 on...
BioSyent logo.png
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Seventh Consecutive Year
May 02, 2022 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 02, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the seventh consecutive year, FeraMAX® is the #1 recommended iron...
BioSyent logo.png
Pour la septième année consécutive, FeraMAXᴹᴰ est le 1ᴱᴿ choix de marque de supplément de fer recommandée par les pharmaciens et les médecins canadiens
May 02, 2022 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, 02 mai 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », Bourse de croissance TSX : RX) a le plaisir d’annoncer que pour la septième année consécutive, FeraMAXMD est le...